Double-blind, placebo-controlled study of risperidone for the treatment of disruptive behaviors in children with subaverage intelligence

American Journal of Psychiatry

Volumn 159, Issue 8, 2002, Pages 1337-1346

  Aman, Michael G ^a   De Smedt, Goedele ^a   Derivan, Albert ^a   Lyons, Ben ^a   Findling, Robert L ^a   Hagerman, Randi ^a   Handen, Benjamin ^a   Hellings, Jessica ^a   Lesem, Michael ^a   Pahl, Jörg ^a   Pearson, Deborah A ^a   Rieser, Michael ^a   Singh, Nirbhay N ^a   Swanson, James ^a  

^a THE OHIO STATE UNIVERSITY WEXNER MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTICONVULSIVE AGENT; ANTIDEPRESSANT AGENT; ANTIHISTAMINIC AGENT; BENZATROPINE; CARBAMAZEPINE; CHLORAL HYDRATE; CHOLINESTERASE INHIBITOR; DEXAMPHETAMINE; DIPHENHYDRAMINE; LITHIUM; MELATONIN; METHYLPHENIDATE; NEUROLEPTIC AGENT; PEMOLINE; PSYCHOSTIMULANT AGENT; RISPERIDONE; TRIHEXYPHENIDYL; VALPROIC ACID;

ARTICLE; ATTENTION DEFICIT DISORDER; BEHAVIOR DISORDER; CHILD; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG TOLERABILITY; DYSPEPSIA; FEMALE; HEADACHE; HUMAN; HYPERACTIVITY; INTELLIGENCE QUOTIENT; IRRITABILITY; LETHARGY; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PRIORITY JOURNAL; PSYCHOSOCIAL WITHDRAWAL; RANDOMIZED CONTROLLED TRIAL; RHINITIS; SCORING SYSTEM; SOMNOLENCE; VISUAL ANALOG SCALE; VOMITING;

AGGRESSION; ANTIPSYCHOTIC AGENTS; ATTENTION DEFICIT AND DISRUPTIVE BEHAVIOR DISORDERS; CHILD; COMORBIDITY; CONDUCT DISORDER; DOUBLE-BLIND METHOD; FEMALE; HUMANS; MALE; MENTAL RETARDATION; PERSONALITY ASSESSMENT; PLACEBOS; RISPERIDONE; TREATMENT OUTCOME;

EID: 0036339405     PISSN: 0002953X     EISSN: None     Source Type: Journal    
DOI: 10.1176/appi.ajp.159.8.1337     Document Type: Article

References (55)

1. The pharmacological treatment of conduct disorders and rage outbursts
2. Aggressive behaviour in childhood
3. American Academy of Child and Adolescent Psychiatry Practice parameters for the assessment and treatment of children and adolescents with conduct disorder
4. Mental retardation and psychiatric disorders
5. Dual diagnoses: Psychiatric disorders in developmental disabilities
6. Diagnosis and treatment of psychiatric and behavioural disorders in mentally retarded individuals: The state of the art
7. Mental disorders and problematic behaviours in people with intellectual disability: Future directions for research
8. Toward a functional analysis of drug treatment for behavior problems of people with developmental disabilities
9. Psychopharmacotherapy in children and adults with intellectual disability
10. Diagnosis and pharmacotherapy of conduct disorder
11. Severe conduct disorder - Some key issues
12. The treatment of conduct disorder: Perspectives from across Canada
13. Effective psychosocial treatments of conduct-disordered children and adolescents: 29 Years, 82 studies, and 5,272 kids
14. Neuroleptics
15. A double-blind pilot study of risperidone in the treatment of conduct disorder
16. Risperidone in the treatment of behavioral disturbances in children and adolescents with borderline intellectual functioning: A double-blind, placebo-controlled pilot trial
17. A randomized controlled trial of risperidone in the treatment of aggression in hospitalized adolescents with subaverage cognitive abilities
18. Risperidone in comorbid ADHD and ODD/CD
19. Case study: Risperidone treatment of children and adolescents with developmental disorders
20. Clinical experience with risperidone
21. Chorea and tardive dyskinesia in a patient taking risperidone
22. Risperidone in the treatment of choreiform movements and aggressiveness in a child with "PANDAS."
23. Risperidone for young children with mood disorders and aggressive behavior
24. Risperidone effects in treatment-resistant adolescents: Preliminary case reports
25. Risperidone in the treatment of two very young children with autism
26. Diet and the atypical neuroleptics
27. Drug therapy in autism
28. Risperidone treatment of children and adolescents with pervasive developmental disorders: A prospective, open-label study
29. Risperidone in young children with pervasive developmental disorders and other developmental disabilities
30. Case study: Anorexia nervosa and autistic disorder in an adolescent girl
31. Use of risperidone in pervasive development disorders: A case series
32. Risperidone augmentation of serotonin reuptake inhibitor treatment of pediatric obsessive compulsive disorder
33. Risperidone treatment forjuvenile bipolar disorder: A retrospective chart review
34. An open clinical trial of risperidone monotherapy in young children with autistic disorder
35. Risperidone as add-on therapy in behavioural disturbances in mental retardation: A double-blind placebo-controlled cross-over study
36. An open trial of risperidone in young autistic children
37. Risperidone and explosive aggressive autism
38. Substituting traditional antipsychotics with risperidone for individuals with mental retardation
39. Brief report: Risperidone for severely disturbed behavior and tardive dyskinesia in developmentally disabled adults
40. Risperidone for aggression and self-injurious behavior in adults with mental retardation
41. Clinical and economic aspects of risperidone treatment in adults with mental retardation and behavioral disturbance
42. Brief report: Two-year control of behavioral symptoms with risperidone in two profoundly retarded adults with autism
43. The Nisonger Child Behavior Rating Form: Age and gender effect and norms
44. The Nisonger CBRF a child behavior rating form for children with developmental disabilities
45. The Aberrant Behavior Checklist: A behavior rating scale for the assessment of treatment effects
46. The Behavior Problems Inventory: An instrument for the assessment of self-injury, stereotyped behavior, and aggression/destruction in individuals with developmental disabilities
47. Applications of computerized cognitive-motor measures to the assessment of psychoactive drugs
48. Extrapyramidal Symptom Rating Scale
49. Cognitive effects of haloperidol and lithium in aggressive conduct-disorder children
50. Atypical antipsychotics and weight gain - A systematic review